Arcutis Biotherapeutics

Develops topical treatments for chronic skin diseases including psoriasis and atopic dermatitis using proprietary drug delivery technologies.

Company Info

Sector:Small Molecule Pharma

Headquarters:Westlake Village, CA, USA

Founded:2016

Website:www.arcutis.com/

Clinical Development Pipeline

Zoryve (roflumilast) cream 0.3%

Target: PDE4

Plaque psoriasis, including intertriginous areas, in patients 2 years and older

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Zoryve (roflumilast) cream 0.15%

Target: PDE4

Atopic dermatitis in adults and children down to 6 years of age

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Zoryve (roflumilast) foam 0.3%

Target: PDE4

Seborrheic dermatitis in individuals aged 9 years and older

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ARQ-154 (topical roflumilast foam)

Target: PDE4

Scalp psoriasis and other inflammatory skin conditions

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

Business & Strategy•Oct 9, 2026•Fierce Pharma

Arcutis' Zoryve sticks the landing with gymnast Simone Biles in new awareness campaign ↗

Arcutis Biotherapeutics has added Olympic gymnast Simone Biles to its roster of celebrity spokespeople for the topical skin medicine Zoryve, fronting a "Skin to Believe In" campaign aimed at the roughly 36 million people in the U.S. living with inflammatory skin conditions.

Leadership Team

Frank Watanabe

President and Chief Executive Officer

Patrick Burnett

Chief Medical Officer

Careers & Job Openings

See all open roles

All

Westlake Village, CA

Apply Now →